Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001…

By S. Aronoff, S. Rosenblatt, S. Braithwaite, J. Egan, A. Mathisen, R. Schneider. Diabetes Care, 2000

640 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3ac1be685c481a3aebaa4d434755ff7d3499156f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Silvio E. Inzucchi

In Molecular Biology

1. Sushil Kumar Jain
2. A. Achari

Citations in the corpus

• Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review (2014, neutral): “rosiglitazone 2–6 mg/twice a day) [65-67].”
• Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, background): “Pioglitazone treatment has been associated with increased risk of the development of edema in type 2 diabetic patients [124].”
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review. (2002, background): “High-density lipoprotein cholesterol concentrations, for instance, increase with TZD therapy and triglyceride concentrations frequently fall.(101,104) The effect on lowdensity lipoprotein cholesterol concen-”